ТРАНСПЛАНТАЦИЯ АУТОЛОГИЧНЫХ ГЕМОПОЭТИЧЕСКИХ СТВОЛОВЫХ КЛЕТОК ПАЦИЕНТАМ С РАССЕЯННЫМ СКЛЕРОЗОМ

Полный текст:


Аннотация

 

Рассеянный склероз (РС) – хроническое заболевание центральной нервной системы, сопровождающееся разнообразными неврологическими симптомами и в течение нескольких лет приводящее к инвалидизации. Лечение РС является одной из наиболее актуальных и сложных проблем практической медицины. Применение имеющихся на сегодняшний день препаратов позволяет лишь снизить частоту и тяжесть обострений, что для лечения хронических неврологических расстройств явно недостаточно. Трансплантация гемопоэтических клеток является одним из перспективных методов лечения РС. В обзоре представлен анализ результатов клинических исследований по применению трансплантации гемопоэтических стволовых клеток при лечении больных РС.



Об авторах

О. Е. Гичкун
Федеральный научный центр трансплантологии и искусственных органов имени академика В. И. Шумакова
Россия


Е. Б. Ярошенко
Федеральный научный центр трансплантологии и искусственных органов имени академика В. И. Шумакова
Россия


А. О. Шевченко
Федеральный научный центр трансплантологии и искусственных органов имени академика В. И. Шумакова
Россия


Список литературы

1. Frohman, E. M. Multiple sclerosis the plaque and its pathogenesis / E. M. Frohman, M. K. Racke, C. S. Raine // N. Engl. J. Med. – 2006. – N 354. – P. 942–955.

2. Рассеянный склероз / под ред. Е. И. Гусева, И.А. Завалишина, А.Н. Бойко. – М.: Реал Тайм, 2011. – 528 с.

3. Dendrou, C. A. Immunopathology of multiple sclerosis / C. A. Dendrou, L. Fugger, M. A. Friese // Nat. Rev. Immunol. – 2015. – Vol. 15, N 9. – Р. 545–558. – doi: 10.1038/nri3871. Epub. 2015 Aug. 7.

4. Riedhammer, C. Antigen presentation, autoantigens, and immune regulation in Multiple sclerosis and other autoimmune diseases / C. Riedhammer, R. Weissert // Front Immunol. – 2015. – Vol. 17, N 6. – Р. 322. – doi: 10.3389/fim-mu.2015.00322. eCollection 2015.

5. Atkins, H. L. Hematopoietic stem cell therapy for multiple sclerosis: top 10 lessons learned / H. L. Atkins, M. S. Freedman // Neurotherapeutics. – 2013. – Vol. 10, N 1. – Р. 68–76. – doi: 10.1007/s13311-012-0162-5.

6. Ribatti, D. The fundamental contribution of Robert A. Good to the discovery of the crucial role of thymus in mammalian immunity / D. Ribatti // Immunology. – 2006. – Vol. 119, N 3. – Р. 291–295.

7. Complications of allogeneic hematopoietic stem cell transplantation / K. Arnaout [et al.] // Cancer Invest. – 2014. – Vol. 32, N 7. – P. 349–362. – doi: 10.3109/07357907.2014.919301. Epub. 2014 June 5.

8. Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation / D. M. Karussis [et al.] // J. Clin. Invest. – 1993. – N 92. – Р. 765–772.

9. Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation / J. A. Snowden [et al.] // Bone Marrow Transplant. – 2012. – N 47. – Р. 770–790.

10. Transplantation for autoimmune diseases in north and south america: a report of the Center for International Blood and Marrow Transplant Research / M. C. Pasquini [et al.] // Biol. Blood Marrow Transplant. – 2012. – N 18. – Р. 1471–1478.

11. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study / A. Fassas [et al.] // Bone Marrow Transplant. – 1997. – Vol. 20, N 8.– P. 631–638. – doi:10.1038/sj. bmt.1700944.

12. Autologous stem cell transplantation in progressive multiple sclerosis – an interim analysis of efficacy / A. Fassas [et al.] // J. Clin. Immunol. – 2000. – Vol. 20, N 1. – P. 24–30.

13. Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study / A. Fassas [et al.] // J. Neurol. – 2002. – Vol. 249, N 8. – P. 1088–1097. – doi:10.1007/s00415-002-08007.

14. High dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis / T. Kozak [et al.] // Bone Marrow Transplant. – 2000. – Vol. 25, N 5. – P. 525-531. – doi:10.1038/sj.bmt.1702180.

15. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring / H. Openshaw [et al.] // Biol. Blood Marrow Transplant. – 2000. – Vol. 6, N 5A. – P. 563–575.

16. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores / R. K. Burt [et al.] // Blood. – 2003. – Vol. 102, N 7. – P. 2373–2378. – doi:10.1182/blood-2003-03-0877.

17. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis / R. A. Nash [et al.] // Blood. – 2003. – Vol. 102, N 7. – P. 2364–2372. – doi:10.1182/blood-2002-12-3908.

18. Clinical and MRI outcome after autologous hematopoietic stem cell transplantation iMS / A. Saiz [et al.] // Neurology. – 2004. – Vol. 62, N 2. – P. 282–284.

19. Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life / R. Saccardi [et al.] // Blood. – 2005. – Vol. 105, N 6. – P. 2601–2607. – doi:10.1182/ blood-2004-08-3205.

20. Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database / R. Saccardi [et al.] // Mult. Scler. – 2006. – Vol. 12, N 6. – P. 814–823.

21. Intense T-cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis / J. P. Samijn [et al.] // J. Neurol. Neurosurg. Psychiatry. – 2006. – Vol. 77, N 1. – P. 46–50. – doi:10.1136/jnnp.2005.063883.

22. Clinical outcomes after autologous haematopoietic stem cell transplantation in patients with progressive multiple sclerosis / J. Xu [et al.] // Chin. Med. J. (Engl.). – 2006. – Vol. 119, N 22. – P. 1851–1855.

23. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis / Y. L. Shevchenko [et al.] // Exp. Hematol. – 2008. – Vol. 36, N 8. – P. 922–928. – doi:10.1016/j.ex-phem.2008.03.001.

24. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing remitting multiple sclerosis: a phase I/II study / R. K. Burt [et al.] // Lancet Neurol. – 2009. – Vol. 8, N 3. – P. 244–253. – doi:10.1016/S1474-4422(09)70017-1.

25. Fagius, J. Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation / J. Fagius, J. G. Lundgren // Oberg. Mult. Scler. – 2009. – Vol. 15, N 2. – P. 229–237. – doi:10.1177/1352458508096875.

26. High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple scle- rosis: a single center 10-year experience / E. Krasulova [et al.] // Mult. Scler. – 2010. – Vol. 16, N 6. – P. 685–693. – doi:10.1177/1352458510364538.

27. Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM/ horse ATG and CY/ rabbit ATG / N. Hamerschlak [et al.] // Bone Marrow Transplant. – 2010. – Vol. 45, N 2. – P. 239–48. – doi:10.1038/bmt.2009.127.

28. Long-term results of stem cell transplantation for MS: a single-center experience / A. Fassas [et al.] // Neurology. – 2011. – Vol. 76, N 12. – P. 1066–1070. – doi:10.1212/WNL.0b013e318211c537. Outcome of HSCT in MS patients after a median follow-up of 11 years.

29. Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis / Y. L. Shevchenko [et al.] // Exp. Hematol. – 2012. – Vol. 40, N 11. – P. 892–898. – doi:10.1016/j.exphem.2012.07.003.

30. Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results / J. D. Bowen [et al.] // Bone Marrow Transplant. – 2012. – Vol. 47, N 7. – P. 946–951. – doi:10.1038/bmt.2011.208.

31. Autologous haematopoietic stem cell transplantation with an intermediaten intensity conditioning regimen in multiple sclerosis: the Italian multi-center experience / G. L. Mancardi [et al.] // Mult. Scler. – 2012. – Vol. 18, N 6. – P. 835–842. – doi:10.1177/1352458511429320. Italian study of autologous HSCT in MS with BEAM/ATG conditioning regimen.

32. Long-term efficacy оf autologous haematopoietic stem cell transplantation in multiple sclerosis at a single institution in China / B. Chen [et al.] // Neurol. Sci. – 2012. – Vol. 33, N 4. – P. 881–886. – doi:10.1007/s100720110859-y.

33. Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience / J. Burman [et al.] // J. Neurol. Neurosurg. Psychiatry. – 2014. – doi:10.1136/jnnp-2013-307207.

34. Havrdova, E. Aggressive multiple sclerosis – is there a role for stem cell transplantation? / E. Havrdova // J. Neurol. – 2005. – N 252 (Suppl. 3). – P. III34–III37.

35. Italian GITMO-NEURO Intergroup on Autologous Stem Cell Transplantation. The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study / L. Roccatagliata [et al.] // Mult. Scler. – 2007. – N 13. – P. 1068–1070.

36. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients / P. A. Muraro [et al.] // J. Exp. Med. – 2005. – N 201. – P. 805–816.

37. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial / G. L. Mancardi [et al.] // Neurology. – 2015. – Vol. 84, N 10. – P. 981–988. – doi: 10.1212/WNL.0000000000001329. Epub. 2015 Feb. 11.


Дополнительные файлы

Для цитирования: Гичкун О.Е., Ярошенко Е.Б., Шевченко А.О. ТРАНСПЛАНТАЦИЯ АУТОЛОГИЧНЫХ ГЕМОПОЭТИЧЕСКИХ СТВОЛОВЫХ КЛЕТОК ПАЦИЕНТАМ С РАССЕЯННЫМ СКЛЕРОЗОМ. Известия Национальной академии наук Беларуси. Серия медицинских наук. 2016;(2):110-117.

For citation: Gichkun O.E., Yaroshenko E.B., Shevchenko A.O. HAEMATOPOIETIC STEM CELL TRANSPLANTATION TO PATIENTS WITH MULTIPLE SCLEROSIS. Proceedings of the National Academy of Sciences of Belarus, Medical series. 2016;(2):110-117. (In Russ.)

Просмотров: 121

Обратные ссылки

  • Обратные ссылки не определены.


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1814-6023 (Print)
ISSN 2524-2350 (Online)